-
1
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
-
(2009)
Diabetes Care
, vol.32
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
-
2
-
-
78651338445
-
Standards of medical care in diabetes - 2011
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 1
-
-
-
4
-
-
77955914623
-
An update on the treatment of type 1 and type 2 diabetes mellitus: Focus on insulin detemir, a long-acting human insulin analog
-
Raslova K. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vasc Health Risk Manag. 2010;6:399-410.
-
(2010)
Vasc Health Risk Manag
, vol.6
, pp. 399-410
-
-
Raslova, K.1
-
5
-
-
58149165212
-
Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence
-
Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6:54-67.
-
(2008)
Clin Med Res
, vol.6
, pp. 54-67
-
-
Hartman, I.1
-
6
-
-
81255141608
-
-
® (insulin glargine [rDNA origin] injection) [prescribing information], NJ: Sanofi-Aventis US
-
® (insulin glargine [rDNA origin] injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; 2010.
-
(2010)
Bridgewater
-
-
-
8
-
-
33746538357
-
Twice-daily compared with oncedaily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart
-
Ashwell SG, Gebbie J, Home PD. Twice-daily compared with oncedaily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23:879-886.
-
(2006)
Diabet Med
, vol.23
, pp. 879-886
-
-
Ashwell, S.G.1
Gebbie, J.2
Home, P.D.3
-
9
-
-
4444307704
-
Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine
-
Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004;66:49-56.
-
(2004)
Diabetes Res Clin Pract
, vol.66
, pp. 49-56
-
-
Garg, S.K.1
Gottlieb, P.A.2
Hisatomi, M.E.3
-
10
-
-
0842311525
-
Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy
-
Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27:632-633.
-
(2004)
Diabetes Care
, vol.27
, pp. 632-633
-
-
Albright, E.S.1
Desmond, R.2
Bell, D.S.3
-
11
-
-
34948861041
-
Refining basal insulin therapy: What have we learned in the age of analogues?
-
Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23:441-454.
-
(2007)
Diabetes Metab Res Rev
, vol.23
, pp. 441-454
-
-
Devries, J.H.1
Nattrass, M.2
Pieber, T.R.3
-
12
-
-
0030887890
-
Crystal structure of a prolonged- acting insulin with albumin-binding properties
-
Whittingham JL, Havelund S, Jonassen I. Crystal structure of a prolonged- acting insulin with albumin-binding properties. Biochemistry. 1997;36:2826-2831.
-
(1997)
Biochemistry
, vol.36
, pp. 2826-2831
-
-
Whittingham, J.L.1
Havelund, S.2
Jonassen, I.3
-
13
-
-
0029886377
-
Albumin binding and time action of acylated insulins in various species
-
Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci. 1996;85:304-308.
-
(1996)
J Pharm Sci
, vol.85
, pp. 304-308
-
-
Kurtzhals, P.1
Havelund, S.2
Jonassen, I.3
Kiehr, B.4
Ribel, U.5
Markussen, J.6
-
14
-
-
77953551138
-
-
® (insulin detemir [rDNA origin] injection) [prescribing information], NJ: Novo Nordisk Inc
-
® (insulin detemir [rDNA origin] injection) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; 2009.
-
(2009)
Princeton
-
-
-
15
-
-
9944261933
-
Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus
-
Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2004;64: 2577-2595.
-
(2004)
Drugs
, vol.64
, pp. 2577-2595
-
-
Chapman, T.M.1
Perry, C.M.2
-
16
-
-
33947644300
-
Albuminbound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes
-
Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albuminbound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-299.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 290-299
-
-
Klein, O.1
Lynge, J.2
Endahl, L.3
Damholt, B.4
Nosek, L.5
Heise, T.6
-
17
-
-
58149199751
-
Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: A double-blind, randomized, crossover study
-
King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11:69-71.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 69-71
-
-
King, A.B.1
-
18
-
-
33645967817
-
Insulin detemir under steady-state conditions: No accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes
-
Bott S, Tusek C, Jacobsen LV, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med. 2006;23:522-528.
-
(2006)
Diabet Med
, vol.23
, pp. 522-528
-
-
Bott, S.1
Tusek, C.2
Jacobsen, L.V.3
-
19
-
-
33746391488
-
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
-
Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
-
(2006)
Diabetes Care
, vol.29
, pp. 1269-1274
-
-
Hermansen, K.1
Davies, M.2
Derezinski, T.3
Ravn, G.M.4
Clauson, P.5
Home, P.6
-
20
-
-
12744274870
-
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes
-
Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7: 56-64.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 56-64
-
-
Haak, T.1
Tiengo, A.2
Draeger, E.3
Suntum, M.4
Waldhausl, W.5
-
21
-
-
39049105019
-
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
-
Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416.
-
(2008)
Diabetologia
, vol.51
, pp. 408-416
-
-
Rosenstock, J.1
Davies, M.2
Home, P.D.3
Larsen, J.4
Koenen, C.5
Schernthaner, G.6
-
22
-
-
57649230070
-
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
-
Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987.
-
(2008)
Clin Ther
, vol.30
, pp. 1976-1987
-
-
Hollander, P.1
Cooper, J.2
Bregnhoj, J.3
Pedersen, C.B.4
-
23
-
-
70350605350
-
Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
-
Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542-548.
-
(2009)
Diabetes Metab Res Rev
, vol.25
, pp. 542-548
-
-
Raskin, P.1
Gylvin, T.2
Weng, W.3
Chaykin, L.4
-
24
-
-
6944244979
-
Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes
-
Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
-
(2004)
Diabetes Res Clin Pract
, vol.66
, pp. 193-201
-
-
Raslova, K.1
Bogoev, M.2
Raz, I.3
Leth, G.4
Gall, M.A.5
Hancu, N.6
-
25
-
-
35048827066
-
The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE™ 303 study
-
Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab. 2007;9: 902-913.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 902-913
-
-
Meneghini, L.1
Koenen, C.2
Weng, W.3
Selam, J.L.4
-
26
-
-
38549131326
-
Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: A subgroup analysis of the US PREDICTIVE 303 study
-
Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin. 2008;24:11-20.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 11-20
-
-
Selam, J.L.1
Koenen, C.2
Weng, W.3
Meneghini, L.4
-
27
-
-
48249139906
-
Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVE™ BMI clinical trial
-
Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVE™ BMI clinical trial. Diabet Med. 2008;25:916-923.
-
(2008)
Diabet Med
, vol.25
, pp. 916-923
-
-
Fajardo Montanana, C.1
Hernandez Herrero, C.2
Rivas Fernandez, M.3
-
28
-
-
33845236398
-
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
-
Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28: 1569-1581.
-
(2006)
Clin Ther
, vol.28
, pp. 1569-1581
-
-
Philis-Tsimikas, A.1
Charpentier, G.2
Clauson, P.3
Martinez Ravn, G.4
Roberts, V.L.5
Thorsteinsson, B.6
-
29
-
-
65549131199
-
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: An assessment of two different fasting plasma glucose targets - the TITRATE study
-
Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab. 2009;11:623-631.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 623-631
-
-
Blonde, L.1
Merilainen, M.2
Karwe, V.3
Raskin, P.4
-
30
-
-
70350534273
-
Three-year efficacy of complex insulin regimens in type 2 diabetes
-
Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361: 1736-1747.
-
(2009)
N Engl J Med
, vol.361
, pp. 1736-1747
-
-
Holman, R.R.1
Farmer, A.J.2
Davies, M.J.3
-
31
-
-
35548947584
-
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
-
Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-1730.
-
(2007)
N Engl J Med
, vol.357
, pp. 1716-1730
-
-
Holman, R.R.1
Thorne, K.I.2
Farmer, A.J.3
-
32
-
-
33947704161
-
PREDICTIVE - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: Baseline characteristics and predictors of hypoglycaemia from the European cohort
-
Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007;9:428-434.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 428-434
-
-
Luddeke, H.J.1
Sreenan, S.2
Aczel, S.3
-
33
-
-
73449139073
-
Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE
-
Fontaine P, Gin H, Pinget M, et al. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE. Adv Ther. 2009;26:535-551.
-
(2009)
Adv Ther
, vol.26
, pp. 535-551
-
-
Fontaine, P.1
Gin, H.2
Pinget, M.3
-
34
-
-
33947636649
-
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE study
-
Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9:418-427.
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 418-427
-
-
Meneghini, L.F.1
Rosenberg, K.H.2
Koenen, C.3
Merilainen, M.J.4
Luddeke, H.J.5
-
35
-
-
34548818137
-
3-month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE study
-
Hermansen K, Lund P, Clemmensen K, et al. 3-month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: the PREDICTIVE study. Rev Diabet Studies. 2007;4:89-97.
-
(2007)
Rev Diabet Studies
, vol.4
, pp. 89-97
-
-
Hermansen, K.1
Lund, P.2
Clemmensen, K.3
-
36
-
-
40449141977
-
Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: Subgroup analysis from the PREDICTIVE study
-
Dornhorst A, Luddeke HJ, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract. 2008;62:659-665.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 659-665
-
-
Dornhorst, A.1
Luddeke, H.J.2
Sreenan, S.3
-
37
-
-
59349118528
-
Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: Results from a subgroup of the PREDICTIVE study
-
Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract. 2009;63:425-432.
-
(2009)
Int J Clin Pract
, vol.63
, pp. 425-432
-
-
Yenigun, M.1
Honka, M.2
-
38
-
-
55949103510
-
Virkamaki A, Zhang K, Hansen JB; PREDICTIVE study group. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: Data from the European cohort of the PREDICTIVE study
-
Sreenan S
-
Sreenan S, Virkamaki A, Zhang K, Hansen JB; PREDICTIVE study group. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract. 2008;62: 1971-1980.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 1971-1980
-
-
-
39
-
-
50049096963
-
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia
-
Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008;10:273-277.
-
(2008)
Diabetes Technol Ther
, vol.10
, pp. 273-277
-
-
Davies, M.J.1
Derezinski, T.2
Pedersen, C.B.3
Clauson, P.4
-
40
-
-
77954927363
-
Diabetes and weight management
-
Lau DC. Diabetes and weight management. Prim Care Diabetes. 2010; 4(Suppl 1):S24-S30.
-
(2010)
Prim Care Diabetes
, vol.4
, Issue.SUPPL. 1
-
-
Lau, D.C.1
-
41
-
-
16844368165
-
Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp
-
Hordern SVM, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia. 2005;48:420-426.
-
(2005)
Diabetologia
, vol.48
, pp. 420-426
-
-
Hordern, S.V.M.1
Wright, J.E.2
Umpleby, A.M.3
Shojaee-Moradie, F.4
Amiss, J.5
Russell-Jones, D.L.6
-
43
-
-
68449088653
-
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5-year randomised, open-label study
-
Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5-year randomised, open-label study. Diabetologia. 2009;52:1971-1973.
-
(2009)
Diabetologia
, vol.52
, pp. 1971-1973
-
-
Rosenstock, J.1
Fonseca, V.2
McGill, J.B.3
-
44
-
-
70949084349
-
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: A meta-analysis
-
Dejgaard A, Lynggaard H, Rastam J, Krogsgaard TM. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52:2507-2512.
-
(2009)
Diabetologia
, vol.52
, pp. 2507-2512
-
-
Dejgaard, A.1
Lynggaard, H.2
Rastam, J.3
Krogsgaard, T.M.4
-
45
-
-
34247219607
-
New global recommendations: A multidisciplinary approach to improving outcomes in diabetes
-
McGill M, Felton AM. New global recommendations: a multidisciplinary approach to improving outcomes in diabetes. Prim Care Diabetes. 2007; 1:49-55.
-
(2007)
Prim Care Diabetes
, vol.1
, pp. 49-55
-
-
McGill, M.1
Felton, A.M.2
-
46
-
-
77954189321
-
The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus
-
Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121:94-107.
-
(2009)
Postgrad Med
, vol.121
, pp. 94-107
-
-
Pi-Sunyer, F.X.1
-
47
-
-
37349093469
-
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE
-
Dornhorst A, Luddeke HJ, Koenen C, et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab. 2008;10:75-81.
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 75-81
-
-
Dornhorst, A.1
Luddeke, H.J.2
Koenen, C.3
-
48
-
-
33847046362
-
Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort
-
Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61:523-528.
-
(2007)
Int J Clin Pract
, vol.61
, pp. 523-528
-
-
Dornhorst, A.1
Luddeke, H.J.2
Sreenan, S.3
|